25 completed, 9 recruiting, 5 active not recruiting, 3 terminated. 48 Phase 1, 7 Phase 2.
Follow Opioid Use Disorder: new trials by email Literature Review of Opioid Use Disorder trials Research Report on Opioid Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo - Opioid Use Disorder, Opioid Withdrawal | Phase 1 / Phase 2 | Not yet recruiting | Clive Michelsen | 60 | 2027-07-01 | 2026-10-13 |
| Cannabis Effects on Opioid Self-Administration Cannabis, Placebo Cannabis, Intranasal Opioid Agonist - Opioid Use Disorder, Cannabis Use | Phase 1 | Not yet recruiting | Shanna Babalonis, PhD | 30 | 2026-11-30 | 2026-10-14 |
| Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder [11C]OMAR - Opioid Use Disorder, OAT | Phase 1 | Recruiting | Yale University | 110 | 2026-10-01 | 2026-10-02 |
| iSTEP-N 101b: Pharmacokinetics and Safety Study of iSTEP-N Implant vs Monthly Vivitrol in Healthy Volunteers Naltrexone implant, 9.6 grams, Extended-release naltrexone injection, 380 mg - Opioid Use Disorder | Phase 1 | Active not recruiting | Akyso Therapeutics, LLC | 21 | 2026-07-25 | 2026-11-12 |
| Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder Transcranial Direct Current Stimulation (tDCS) - Opioid Use Disorder | Phase 1 | Recruiting | University of Minnesota | 40 | 2026-02-04 | 2026-07-06 |
| Autonomous Digital CBT Intervention for Opioid Use Disorder in Individuals With Co-Occurring Internalizing Disorders NEAT-O program - Opioid Use Disorder, Anxiety | Phase 1 | Active not recruiting | University of Minnesota | 17 | 2025-08-21 | 2026-02-12 |
| Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder Guanfacine pharmacotherapy, Mindfulness Oriented Recovery Enhancement (MORE) - Mindfulness, Guanfacine | Phase 1 | Recruiting | Rutgers, The State University of New Jersey | 224 | 2025-07-15 | 2025-08-08 |
| Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings Telemedicine Buprenorphine Treatment - Opioid Use Disorder | Phase 1 | Recruiting | Boulder Care | 250 | 2025-06-10 | 2025-09-11 |
| A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects LUCEMYRA (lofexidine) tablets - Opioid Withdrawal (Disorder), Opioid Use Disorder | Phase 1 | Withdrawn | USWM, LLC (dba US WorldMeds) | 2025-06-01 | 2025-08-01 | |
| Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) Psilocybin - Opioid Use Disorder | Phase 1 | Recruiting | Yale University | 12 | 2025-05-28 | 2026-07-07 |
| A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine BI 1356225, Placebo - Opioid Use Disorder | Phase 1 | Terminated | Boehringer Ingelheim | 12 | 2025-01-27 | 2026-07-31 |
| Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder Tezampanel, Placebo - Opioid Use Disorder | Phase 1 | Recruiting | Proniras Corporation | 40 | 2024-10-16 | 2026-09-17 |
| Cannabis and Opioid Use Disorder Inhaled vaporized cannabis, Intransal opioid - Opioid Use Disorder | Phase 1 | Recruiting | Shanna Babalonis, PhD | 15 | 2024-09-10 | 2026-06-18 |
| Study of the BIOPIN 6 Naltrexone Implant in Healthy Adults BIOPIN-6 Active Implant with Naltrexone, BIOPIN-6 Placebo Implant - Opioid Use Disorder | Phase 1 | Completed | Akyso Therapeutics, LLC | 16 | 2024-06-24 | 2026-04-28 |
| Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder Buprenorphine - Opioid Use Disorder | Phase 1 | Completed | Brigham and Women's Hospital | 18 | 2024-06-04 | 2025-10-23 |
| Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2). AZD4041, Itraconazole, Buprenorphine - Opioid Use Disorder | Phase 1 | Terminated | AstraZeneca | 15 | 2024-05-13 | 2025-03-26 |
| Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System [11C]-PHNO, Calcitriol, Placebo Control - Opioid Use Disorder | Phase 1 | Completed | Yale University | 5 | 2024-03-13 | 2025-11-14 |
| SafeMedWaste At-Home, Environmentally-Friendly Opioid Disposal Kit for Orthopedic Post-Operative Surgical Patients to Reduce Opioids Available for Diversion SafeMedWaste - Opioid Use Disorder | Phase 1 | Unknown | SafeMedWaste, Inc. | 300 | 2024-02-01 | 2024-01-22 |
| Hyperbaric Oxygen Treatment (HBOT) During Methadone Tapering Hyperbaric Oxygen Treatment Full, Hyperbaric Oxygen Treatment Sham, Hyperbaric Oxygen Treatment Partial Pressure - Opioid Use Disorder | Phase 1 | Completed | Washington State University | 25 | 2023-12-04 | 2026-06-04 |
| Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion Placebo, Auvelity - Addiction, Opioid Use | Phase 1 / Phase 2 | Completed | Virginia Commonwealth University | 18 | 2023-09-18 | 2026-08-19 |
Showing 20 of 48. Sign in to see all of them.
Opioid-Related Disorders (48) · Substance-Related Disorders (4) · Behavior, Addictive (2) · Chronic Pain (2) · Marijuana Abuse (2) · Anxiety Disorders (1) · Chemically-Induced Disorders (1) · Depression (1) · Depressive Disorder (1) · Digestive System Diseases (1) · Heroin Dependence (1) · Hyperalgesia (1) · Mental Disorders (1) · Motor Activity (1) · Opiate Overdose (1)
Narcotic-Related Disorders (48) · Chemically-Induced Disorders (47) · Mental Disorders (47) · Substance-Related Disorders (44) · Behavior (4) · Pathological Conditions, Signs and Symptoms (3) · Compulsive Behavior (2) · Disease Attributes (2) · Impulsive Behavior (2) · Neurologic Manifestations (2) · Pathologic Processes (2) · Signs and Symptoms (2) · Behavioral Symptoms (1) · Chronic Disease (1) · Drug Misuse (1)
Buprenorphine (4) · Buprenorphine, Naloxone Drug Combination (4) · Naltrexone (4) · Morphine (3) · 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (2) · Cannabidiol (2) · Naloxone (2) · Oxytocin (2) · Psilocybin (2) · carfentanil (2) · lofexidine (2) · 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific) (1) · 3-chloro-4-(4-((2-(3-pyridyl)pyrrolidin-1-yl)methyl)phenoxy)benzamide (1) · ASP8062 (1) · Analgesics, Opioid (1)
Yale University (5) · Indivior Inc. (4) · New York State Psychiatric Institute (3) · Akyso Therapeutics, LLC (2) · Astellas Pharma Global Development, Inc. (2) · AstraZeneca (2) · Shanna Babalonis, PhD (2) · University of Minnesota (2) · Virginia Commonwealth University (2) · Boehringer Ingelheim (1) · Boulder Care (1) · Brigham and Women's Hospital (1) · Brown University (1) · Center for Social Innovation, Massachusetts (1) · Cerevel Therapeutics, LLC (1)
United States (47)
Anahita Bassir Nia, MD (2) · Shanna Babalonis, PhD (2) · Adam Bisaga, MD (1) · Andrea Baron, MPH (1) · Annabelle Belcher, PhD (1) · Aynur Unalp-Arida, MD, PhD (1) · Cecilia L Bergeria, PhD (1) · Christopher S Stauffer, MD (1) · Debra Kelsh, MD (1) · Elizabeth Evans, MD (1) · Frederick G Moeller (1) · Frederick G Moeller, MD (1) · Gustavo Angarita, MD, MHS (1)
PMID 10870744, PMID 11165371, PMID 11786502, PMID 14621285, PMID 15647484, PMID 15800228, PMID 16508405, PMID 17123731, PMID 17237664, PMID 17433624, PMID 17635557, PMID 17853395, PMID 18294378, PMID 18362258, PMID 18378801, PMID 18419722, PMID 18619874, PMID 18774343, PMID 19409861, PMID 19789074, PMID 20031953, PMID 20086062, PMID 21029787, PMID 21148579, PMID 21249671, PMID 21412914, PMID 21765969, PMID 22336864, PMID 22494121, PMID 22898544, PMID 24661411, PMID 24867013, PMID 25221944, PMID 25418676, PMID 25872113, PMID 25957198, PMID 26029937, PMID 26987082, PMID 27407096, PMID 28074005, PMID 28106092, PMID 28119481, PMID 28409480, PMID 28767350, PMID 29671994, PMID 29769209, PMID 30325859, PMID 30325862, PMID 31089778, PMID 31404020
U54DA037842 (2), UG3DA051392 (2), 1UG3DA061620 (1), 4UH3DA052166-02 (1), 5UG1DA050207 (1), 5UG3DA048338-02 (1), IK2CX002286 (1), K12DA000167 (1), P20GM130414 (1), R01DA054347 (1), R01DA063712 (1), R01DK132709 (1), R21DA046030 (1), R21DA052864 (1), R43DA057750 (1)